Peptide

Goserelin (Zoladex)

FDA-approved product existsGH axis & hormones
Not yet scored

BioHarmony verdict

Awaiting review

No BioHarmony report yet. It is queued for review; until then, rely on the status and sources below.

What is Goserelin (Zoladex)?

FDA-approved goserelin is marketed as Zoladex implants for product-specific uses in prostate cancer, breast cancer, endometriosis, and endometrial thinning.

Dosing as published

Approved labelZOLADEX 3.6 mg prescribing information for its approved oncology and gynecologic indications
PopulationAdults covered by the approved ZOLADEX indications
DoseOne 3.6 mg implant
RouteSubcutaneous implant in the upper abdominal wall by a healthcare professional
FrequencyEvery 28 days
DurationIndication-specific; the label specifies 6 months for endometriosis
PreparationReady-to-use 3.6 mg implant supplied in a single-dose prefilled syringe; no reconstitution.
Source: Dosage and Administration sections 2.1-2.7; Dosage Forms and Strengths section 3

More reported protocols

Members

Members can compare additional reported doses, schedules, and preparation notes.

Trust & sourcing

US approvalFDA-approved product exists
CompoundingFDA-approved product exists; compounded copies are not FDA approved
Last checked2026-07-13
Next review2026-10-11

Primary sources

Free guide

The Ultimate Peptides Guide

Spot stronger candidates, weak evidence, and seller red flags before you buy.

Free. Includes evidence and regulatory updates. Unsubscribe anytime.